Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C38H47Br2N9O5 |
Molar mass | 869.660 g·mol−1 |
3D model ( JSmol) | |
| |
|
Olcegepant ( INN, [1] code name BIBN-4096BS) is a calcitonin gene-related peptide receptor antagonist being studied as a potential treatment for migraines. [2]
A 2013 meta-analysis found olcegepant and telcagepant were effective and safe compared to placebo. [3]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C38H47Br2N9O5 |
Molar mass | 869.660 g·mol−1 |
3D model ( JSmol) | |
| |
|
Olcegepant ( INN, [1] code name BIBN-4096BS) is a calcitonin gene-related peptide receptor antagonist being studied as a potential treatment for migraines. [2]
A 2013 meta-analysis found olcegepant and telcagepant were effective and safe compared to placebo. [3]